Eyenovia Company Leadership
| EYEN Stock | USD 0.11 0.02 19.05% |
Eyenovia's insiders are aggressively buying. The analysis of insiders' sentiment of trading Eyenovia stock suggests that virtually all insiders are extremely bullish at this time. Eyenovia employs about 57 people. The company is managed by 8 executives with a total tenure of roughly 133 years, averaging almost 16.0 years of service per executive, having 7.13 employees per reported executive.
Eyenovia's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-08-28 | Michael M Rowe | Acquired 27071 @ 0.52 | View | ||
| 2024-08-26 | Michael M Rowe | Acquired 50000 @ 0.57 | View | ||
| 2024-07-02 | Stuart M Grant | Acquired 1515151 @ 0.66 | View | ||
| 2024-03-28 | Stuart M Grant | Acquired 100000 @ 0.98 | View | ||
| 2024-03-19 | Stuart M Grant | Acquired 50000 @ 1.23 | View | ||
| 2024-03-08 | Stuart M Grant | Acquired 10717 @ 1.58 | View | ||
| 2023-12-04 | Michael M Rowe | Acquired 4890 @ 1.36 | View |
Monitoring Eyenovia's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Eyenovia |
Eyenovia Management Team Effectiveness
The company has return on total asset (ROA) of (0.9294) % which means that it has lost $0.9294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.1466) %, meaning that it created substantial loss on money invested by shareholders. Eyenovia's management efficiency ratios could be used to measure how well Eyenovia manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -1.07. In addition to that, Return On Capital Employed is likely to drop to -1.39. At this time, Eyenovia's Debt To Assets are very stable compared to the past year.As of the 25th of November 2024, Common Stock Shares Outstanding is likely to drop to about 21.5 M. In addition to that, Net Loss is likely to drop to about (12.1 M)
Eyenovia Workforce Comparison
Eyenovia is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,654. Eyenovia holds roughly 57.0 in number of employees claiming about 2.15% of equities under Health Care industry.
Eyenovia Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eyenovia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eyenovia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Eyenovia insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andrew Jones over two weeks ago Acquisition by Andrew Jones of 200000 shares of Eyenovia at 0.5501 subject to Rule 16b-3 | ||
Benjamin Stephen Keith over two months ago Insider Trading | ||
Strahlman Ellen R over two months ago Acquisition by Strahlman Ellen R of 6744 shares of Eyenovia at 1.6018 subject to Rule 16b-3 | ||
Andrew Jones over two months ago Insider Trading | ||
Michael Rowe over two months ago Acquisition by Michael Rowe of 27071 shares of Eyenovia at 0.52 subject to Rule 16b-3 | ||
Michael Rowe over three months ago Acquisition by Michael Rowe of 50000 shares of Eyenovia at 0.57 subject to Rule 16b-3 | ||
Grant Stuart M. over three months ago Acquisition by Grant Stuart M. of 3264931 shares of Eyenovia at 0.69 subject to Rule 16b-3 | ||
Geltzeiler Michael S over three months ago Acquisition by Geltzeiler Michael S of 61481 shares of Eyenovia subject to Rule 16b-3 |
Eyenovia Notable Stakeholders
An Eyenovia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eyenovia often face trade-offs trying to please all of them. Eyenovia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eyenovia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Rowe | President CEO | Profile | |
| John CPA | CFO Secretary | Profile | |
| Andrew Jones | Chief Officer | Profile | |
| Bren Kern | VP Operations | Profile | |
| Tony Cardinale | Vice Sales | Profile | |
| Norbert Lowe | Senior Operations | Profile | |
| Alexander Lobo | Investor Contact | Profile | |
| MD MPH | President, CoFounder | Profile |
About Eyenovia Management Performance
The success or failure of an entity such as Eyenovia often depends on how effective the management is. Eyenovia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eyenovia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eyenovia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (1.32) | (1.39) | |
| Return On Assets | (0.95) | (0.99) | |
| Return On Equity | (3.03) | (3.18) |
Eyenovia Workforce Analysis
Traditionally, organizations such as Eyenovia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eyenovia within its industry.Eyenovia Manpower Efficiency
Return on Eyenovia Manpower
| Revenue Per Employee | 66.44 | |
| Revenue Per Executive | 473 | |
| Net Loss Per Employee | 478.3K | |
| Net Loss Per Executive | 3.4M | |
| Working Capital Per Employee | 196.1K | |
| Working Capital Per Executive | 1.4M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.001 | Quarterly Revenue Growth 4 | Return On Assets (0.93) | Return On Equity (9.15) |
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.